Robert A Weinberg

List of Publications by Year in Descending Order

128 papers	137,702 citations	90 h-index	139 g-index
139 ext. papers	157,587 ext. citations	29.6 avg, IF	9.35 L-index

#	Paper	IF	Citations
128	Leveraging immunochemotherapy for treating pancreatic cancer. *Cell Research*, **2021**, 31, 1228-1229	24.7	0
127	An EMT-primary cilium-GLIS2 signaling axis regulates mammogenesis and claudin-low breast tumorigenesis. *Science Advances*, **2021**, 7, eabf6063	14.3	4
126	Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. *Cancer Discovery*, **2021**, 11, 384-407	24.4	18
125	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. *Cancer Discovery*, **2021**, 11, 362-383	24.4	15
124	Direct and Indirect Regulators of Epithelial-Mesenchymal Transition-Mediated Immunosuppression in Breast Carcinomas. *Cancer Discovery*, **2021**, 11, 1286-1305	24.4	18
123	Linking EMT programmes to normal and neoplastic epithelial stem cells. *Nature Reviews Cancer*, **2021**, 21, 325-338	31.3	63
122	Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. *Nature Communications*, **2021**, 12, 5680	17.4	7
121	David M. Livingston (1941-2021).. *Cancer Cell*, **2021**, 39, 1560-1561	24.3	
120	Emerging Mechanisms by which EMT Programs Control Stemness. *Trends in Cancer*, **2020**, 6, 775-780	12.5	53
119	Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. *Nature*, **2020**, 585, 603-608	50.4	121
118	Guidelines and definitions for research on epithelial-mesenchymal transition. *Nature Reviews Molecular Cell Biology*, **2020**, 21, 341-352	48.7	469
117	Syndecan-Mediated Ligation of ECM Proteins Triggers Proliferative Arrest of Disseminated Tumor Cells. *Cancer Research*, **2019**, 79, 5944-5957	10.1	3
116	EMT and Cancer: More Than Meets the Eye. *Developmental Cell*, **2019**, 49, 313-316	10.2	122
115	Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 7353-7362	11.5	186
114	Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 16971-16980	11.5	61
113	How TP53 (almost) became an oncogene. *Journal of Molecular Cell Biology*, **2019**, 11, 531-533	6.3	0
112	New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. *Nature Reviews Molecular Cell Biology*, **2019**, 20, 69-84	48.7	1131

111	Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nature Medicine*, **2018**, 24, 541-550	50.5	1772
110	The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. *Science Translational Medicine*, **2018**, 10,	17.5	207
109	Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. *Frontiers of Medicine*, **2018**, 12, 361-373	12	260
108	Epithelial-Mesenchymal Transition Induces Podocalyxin to Promote Extravasation via Ezrin Signaling. *Cell Reports*, **2018**, 24, 962-972	10.6	28
107	IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. *Nature Cell Biology*, **2018**, 20, 1084-1097	23.4	75
106	An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. *ELife*, **2018**, 7,	8.9	47
105	Emerging Biological Principles of Metastasis. *Cell*, **2017**, 168, 670-691	56.2	1404
104	Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E2337-E2346	11.5	165
103	EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. *Nature Reviews Clinical Oncology*, **2017**, 14, 611-629	19.4	1172
102	Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. *Cancer Research*, **2017**, 77, 3982-3989	10.1	187
101	LACTB is a tumour suppressor that modulates lipid metabolism and cell state. *Nature*, **2017**, 543, 681-686	50.4	93
100	EMT programs promote basal mammary stem cell and tumor-initiating cell stemness by inducing primary ciliogenesis and Hedgehog signaling. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E10532-E10539	11.5	74
99	Upholding a role for EMT in breast cancer metastasis. *Nature*, **2017**, 547, E1-E3	50.4	198
98	Upholding a role for EMT in pancreatic cancer metastasis. *Nature*, **2017**, 547, E7-E8	50.4	161
97	Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. *Journal of Experimental Medicine*, **2017**, 214, 2243-2255	16.6	128
96	Inflammation Triggers Zeb1-Dependent Escape from Tumor Latency. *Cancer Research*, **2016**, 76, 6778-6784	10.1	90
95	EMT, cell plasticity and metastasis. *Cancer and Metastasis Reviews*, **2016**, 35, 645-654	9.6	469
94	Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. *Science*, **2016**, 351, aad3680	33.3	203

93	Targeting the Epithelial-to-Mesenchymal Transition: The Case for Differentiation-Based Therapy. *Cold Spring Harbor Symposia on Quantitative Biology*, **2016**, 81, 11-19	3.9	46
92	Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. *Cancer Discovery*, **2016**, 6, 630-49	24.4	257
91	Stem cells. Asymmetric apportioning of aged mitochondria between daughter cells is required for stemness. *Science*, **2015**, 348, 340-3	33.3	344
90	Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. *Trends in Cell Biology*, **2015**, 25, 675-686	18.3	664
89	Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. *Nature*, **2015**, 525, 256-60	50.4	464
88	How does multistep tumorigenesis really proceed?. *Cancer Discovery*, **2015**, 5, 22-4	24.4	107
87	Coming full circle-from endless complexity to simplicity and back again. *Cell*, **2014**, 157, 267-71	56.2	163
86	The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. *Nature Cell Biology*, **2014**, 16, 717-27	23.4	569
85	A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. *Nature Cell Biology*, **2014**, 16, 1105-17	23.4	294
84	Tackling the cancer stem cells - what challenges do they pose?. *Nature Reviews Drug Discovery*, **2014** , 13, 497-512	64.1	672
83	Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. *Cell*, **2014**, 158, 1094-1109	56.2	146
82	The epithelial-mesenchymal transition factor SNAIL paradoxically enhances reprogramming. *Stem Cell Reports*, **2014**, 3, 691-8	8	63
81	Protein kinase C [illegible] is a central signaling node and therapeutic target for breast cancer stem cells. *Cancer Cell*, **2013**, 24, 347-64	24.3	231
80	The epigenetics of epithelial-mesenchymal plasticity in cancer. *Nature Medicine*, **2013**, 19, 1438-49	50.5	851
79	An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. *Cancer Cell*, **2013**, 24, 481-98	24.3	126
78	Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. *Cell*, **2013**, 154, 61-74	56.2	608
77	Slug and Sox9 cooperatively determine the mammary stem cell state. *Cell*, **2012**, 148, 1015-28	56.2	685
76	Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. *Seminars in Cancer Biology*, **2012**, 22, 396-403	12.7	672

75	Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. *Cancer Discovery*, **2012**, 2, 840-55	24.4	252
74	The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. *Cancer Discovery*, **2012**, 2, 706-21	24.4	157
73	Bengt Westermark and our current understanding of tumor pathogenesis. *Upsala Journal of Medical Sciences*, **2012**, 117, 81-2	2.8	0
72	Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. *Cell*, **2011**, 145, 926-40	56.2	683
71	Tumor metastasis: molecular insights and evolving paradigms. *Cell*, **2011**, 147, 275-92	56.2	2474
70	Hunting the elusive oncogene: a stroke of good luck. *Nature Cell Biology*, **2011**, 13, 876	23.4	2
69	A perspective on cancer cell metastasis. *Science*, **2011**, 331, 1559-64	33.3	3118
68	Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. *Seminars in Cancer Biology*, **2011**, 21, 99-106	12.7	97
67	Hallmarks of cancer: the next generation. *Cell*, **2011**, 144, 646-74	56.2	39819
66	Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells?. *International Journal of Cancer*, **2011**, 129, 2310-4	7.5	164
65	Roles for microRNAs in the regulation of cell adhesion molecules. *Journal of Cell Science*, **2011**, 124, 999-1006	5.9	84
64	Activation of miR-31 function in already-established metastases elicits metastatic regression. *Genes and Development*, **2011**, 25, 646-59	12.6	85
63	Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 7950-5	11.5	881
62	miR-31: a crucial overseer of tumor metastasis and other emerging roles. *Cell Cycle*, **2010**, 9, 2124-9	4.7	96
61	Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 20009-14	11.5	545
60	Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. *Cancer Research*, **2010**, 70, 5147-54	10.1	97
59	Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 15449-54	11.5	759
58	Metastasis suppression: a role of the Dice(r). *Genome Biology*, **2010**, 11, 141	18.3	7

57	MicroRNAs: Crucial multi-tasking components in the complex circuitry of tumor metastasis. *Cell Cycle*, **2009**, 8, 3506-12	4.7	71
56	Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 10290-5	11.5	274
55	Assaying microRNA loss-of-function phenotypes in mammalian cells: emerging tools and their potential therapeutic utility. *RNA Biology*, **2009**, 6, 541-5	4.8	12
54	Concomitant suppression of three target genes can explain the impact of a microRNA on metastasis. *Genes and Development*, **2009**, 23, 2592-7	12.6	93
53	Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nature Reviews Cancer*, **2009**, 9, 265-73	31.3	2572
52	A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. *Cell*, **2009**, 137, 1032-46	56.2	744
51	Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell*, **2009**, 138, 645-659	56.2	1898
50	The basics of epithelial-mesenchymal transition. *Journal of Clinical Investigation*, **2009**, 119, 1420-8	15.9	6696
49	Ma et al. reply. *Nature*, **2008**, 455, E9-E9	50.4	1
48	Twisted epithelial-mesenchymal transition blocks senescence. *Nature Cell Biology*, **2008**, 10, 1021-3	23.4	68
47	Leaving home early: reexamination of the canonical models of tumor progression. *Cancer Cell*, **2008** , 14, 283-4	24.3	49
46	The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell*, **2008**, 133, 704-15	56.2	6611
45	Systemic endocrine instigation of indolent tumor growth requires osteopontin. *Cell*, **2008**, 133, 994-1005	56.2	336
44	Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. *Developmental Cell*, **2008**, 14, 818-29	10.2	2357
43	Mechanisms of malignant progression. *Carcinogenesis*, **2008**, 29, 1092-5	4.6	131
42	Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. *Cancer Research*, **2008**, 68, 3645-54	10.1	1100
41	The many faces of tumor dormancy. *Apmis*, **2008**, 116, 548-551	3.4	28
40	The many faces of tumor dormancy. *Apmis*, **2008**, 116, 548-51	3.4	21

39	Is metastasis predetermined?. *Molecular Oncology*, **2007**, 1, 263-4; author reply 265-6	7.9	11
38	Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature*, **2007**, 449, 682-8	50.4	2138
37	Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. *Cancer Cell*, **2007**, 12, 160-70	24.3	255
36	Heterogeneity of stromal fibroblasts in tumors. *Cancer Biology and Therapy*, **2007**, 6, 618-9	4.6	111
35	The Spemann organizer gene, Goosecoid, promotes tumor metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 18969-74	11.5	172
34	Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell*, **2005**, 121, 335-48	56.2	2836
33	The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. *Nature Genetics*, **2005**, 37, 1047-54	36.3	363
32	Inadvertent cancer research. *Cancer Biology and Therapy*, **2004**, 3, 238-9	4.6	5
31	Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell*, **2004**, 117, 927-39	56.2	2996
30	A progression puzzle. *Nature*, **2002**, 418, 823	50.4	632
29	Metastasis: objections to the same-gene model. *Nature*, **2002**, 419, 560-560	50.4	5
28	Enumeration of the simian virus 40 early region elements necessary for human cell transformation. *Molecular and Cellular Biology*, **2002**, 22, 2111-23	4.8	528
27	The hallmarks of cancer. *Cell*, **2000**, 100, 57-70	56.2	20934
26	Inhibition of telomerase limits the growth of human cancer cells. *Nature Medicine*, **1999**, 5, 1164-70	50.5	883
25	Creation of human tumour cells with defined genetic elements. *Nature*, **1999**, 400, 464-8	50.4	1892
24	Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. *Oncogene*, **1998**, 16, 1217-22	9.2	349
23	Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. *Nature Genetics*, **1998**, 19, 182-6	36.3	338
22	The expanding role of cell cycle regulators. *Science*, **1998**, 280, 1035-6	33.3	90

21	Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. *Nature*, **1997**, 386, 796-804	50.4	645
20	A specific role for cyclin D1 in mammary gland development. *Journal of Mammary Gland Biology and Neoplasia*, **1997**, 2, 335-42	2.4	49
19	Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. *Nature*, **1996**, 384, 470-4	50.4	611
18	The molecular basis of oncogenes and tumor suppressor genes. *Annals of the New York Academy of Sciences*, **1995**, 758, 331-8	6.5	106
17	Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. *Nature Genetics*, **1994**, 7, 353-61	36.3	664
16	Oncogenes and tumor suppressor genes. *Ca-A Cancer Journal for Clinicians*, **1994**, 44, 160-70	220.7	98
15	Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. *Nature*, **1993**, 363, 45-51	50.4	1184
14	Association between GTPase activators for Rho and Ras families. *Nature*, **1992**, 359, 153-4	50.4	302
13	Effects of an Rb mutation in the mouse. *Nature*, **1992**, 359, 295-300	50.4	1599
12	The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. *Nature*, **1984**, 312, 513-6	50.4	1002
11	Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. *Nature* , **1984**, 312, 649-51	50.4	684
10	Alteration of the genomes of tumor cells. *Cancer*, **1983**, 51, 1971-5	6.4	22
9	Characterization of a human colon/lung carcinoma oncogene. *Nature*, **1983**, 302, 79-81	50.4	196
8	Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. *Nature*, **1983**, 304, 596-602	50.4	2620
7	Isolation of a transforming sequence from a human bladder carcinoma cell line. *Cell*, **1982**, 29, 161-9	56.2	725
6	Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. *Nature*, **1982**, 297, 474-8	50.4	793
5	Mechanism of activation of a human oncogene. *Nature*, **1982**, 300, 143-9	50.4	1271
4	Unique transforming gene in carcinogen-transformed mouse cells. *Nature*, **1981**, 289, 607-9	50.4	88

3	Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. *Nature*, **1981**, 290, 261-4	50.4	710
2	In vitro synthesis of infectious DNA of murine leukaemia virus. *Nature*, **1977**, 269, 122-6	50.4	77
1	The Molecular Basis of Retinoblastomas. *Novartis Foundation Symposium*,99-116		